News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–28
Matches
28
Sources here
11
Companies here
1
Search results Stored financial headlines

Active search

28 matching headlines

Ticker or company: SLDBMain company stories
Clear
Latest

Stock Titan Deals and strategy

Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits

Perceptive Advisors LLC and related entities, including Joseph Edelman, have reported a beneficial ownership of 12,046,579 shares in Solid Biosciences Inc. (NASDAQ: SLDB), representing an 11.2% stake. This includes common stock and pre-funded warrants, with the latter subject to a 9.99% beneficial ownership limitation preventing their current exercise. The filing details the breakdown of shares held by Perceptive …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Stock Titan Market update Main company 🇺🇸 United States

Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketBeat Earnings Main company 🇺🇸 United States

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

HC Wainwright has revised its Q3 2026 earnings estimate for Solid Biosciences (NASDAQ:SLDB), predicting a narrowed loss of $0.38 per share and maintaining a "Buy" rating with a $25 price target. The firm anticipates Solid Biosciences will become profitable by 2029, projecting earnings of …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Market update Main company 🇺🇸 United States

Form 8K Solid Biosciences LLC For: 6 August By Investing.com

This article reports on Solid Biosciences LLC's Form 8K filing for August 6th. It is a brief announcement from Investing.com, providing only the date of the filing and the company involved. The article includes various market data and news unrelated to the specific Form …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB

Dimensional Fund Advisors LP has increased its stake in Solid Biosciences Inc. (NASDAQ:SLDB) by 40.8%, purchasing an additional 277,051 shares to now own 956,135 shares valued at approximately $6.88 million. Institutional investors collectively hold 81.46% of SLDB. The company recently reported a quarterly loss …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

Citizens reiterates Solid Biosciences stock rating on pipeline progress

Citizens has reiterated its Market Outperform rating and $15.00 price target for Solid Biosciences (NASDAQ:SLDB), citing pipeline progress, particularly with its Duchenne muscular dystrophy gene therapy SGT-003. The company also expects to dose patients with a new gene therapy, SGT-501, in the second half …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview

Solid Biosciences Inc (SLDB) is projected to report a loss of 48 cents per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article encourages readers to access the full report for more details.

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS

Solid Biosciences (NASDAQ:SLDB) reported its quarterly earnings, beating analyst estimates by $0.08 with an EPS of ($0.38). The company's stock traded down at $8.39, with a market capitalization of $826 million. Despite recent institutional investor activity and a generally positive "Moderate Buy" consensus rating …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Analyst action Main company 🇺🇸 United States

Solid Biosciences Inc. Stock 12‑Month Price Target Cut to $17.64, Implies 102% Upside

Solid Biosciences Inc. (SLDB) has seen its average 12-month price target slightly decrease from $17.73 to $17.64, according to estimates from 11 analysts. Despite the minor reduction, this updated target suggests a potential upside of approximately 102% based on the August 6 closing price. …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Canada Earnings Main company 🇺🇸 United States

Solid Biosciences files prospectus supplement for up to $200 million stock offering

Solid Biosciences (NASDAQ:SLDB) has filed a prospectus supplement for a potential stock offering of up to $200 million to raise capital. This offering replaces a previous one for $85 million, under which the company had already sold shares totaling approximately $85 million. The biotech …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Solid Biosciences (NASDAQ: SLDB) sets $200M stock sale capacity

Solid Biosciences Inc. has filed a prospectus supplement to offer and sell up to $200.0 million in common stock through an Amended and Restated Sales Agreement with Jefferies LLC. This new capacity replaces a previous $85.0 million offering, which has already been fully utilized. …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Solid Biosciences Inc. Q2 2026: Revenue $0 Net loss $(54.8M), EPS $(0.38) — 10-Q Summary

Solid Biosciences Inc. reported its Q2 2026 financial results, showing no product revenue and an increased net loss of $(54.8M), up from $(39.5M) in Q2 2025. The company's diluted EPS was $(0.38). Despite the financial loss, Solid Biosciences highlighted progress in its clinical pipeline …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Earnings Main company 🇺🇸 United States

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported its second-quarter 2026 financial results, highlighting progress in its Duchenne, Friedreich’s ataxia, and cardiac disease programs. The company expects to meet with the FDA in late Q4 2026 regarding its Duchenne program (SGT-003) for potential accelerated approval, and initial data for …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Solid Biosciences starts Duchenne Phase 3 trial; Phase 1/2 has 53 dosed

Solid Biosciences reported its Q2 2026 financial results, including a net loss of $54.8 million, but highlighted strong cash reserves of $377.7 million, extending its runway into mid-2028. The company provided updates on its clinical programs, noting that its Duchenne gene therapy (SGT-003) has …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

FMR LLC and Abigail Johnson (SLDB) disclose 7% beneficial stake in Solid Biosciences

FMR LLC and Abigail P. Johnson have disclosed a 7% beneficial ownership stake in Solid Biosciences Inc. (SLDB) through a Schedule 13G filing. As of June 30, 2026, they beneficially owned 6,875,956.68 shares of common stock. FMR LLC holds sole voting power over 6,875,423 …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Solid Biosciences (SLDB) Expected to Release Quarterly Earnings on Tuesday

Solid Biosciences (SLDB) is set to release its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.43 per share. The clinical-stage biotechnology company, focused on gene therapies for Duchenne muscular dystrophy, recently saw its stock trade …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Solid Biosciences Inc (SLDB) Financial Health: Profitability & Balance Sheet Analysis

Solid Biosciences Inc (SLDB) has a current financial score of 6.75, placing it 209th out of 384 companies in the Biotechnology & Medical Research industry. Despite a robust financial status, the company's operating efficiency is low. The article notes that relevant data for several …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

BlackRock (SLDB holder) discloses 6.5% Solid Biosciences stake in Schedule 13G

BlackRock, Inc. has filed a Schedule 13G, disclosing a beneficial ownership of 6,419,730 shares of Solid Biosciences Inc. common stock, which represents 6.5% of the outstanding class. The filing indicates BlackRock holds sole voting power over 6,328,941 shares and sole dispositive power over all …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Solid Biosciences Inc (SLDB), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. While the stock currently shows a neutral signal based on technical analysis, it highlights specific …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Solid Biosciences Inc (SLDB) Institutional Confidence

Solid Biosciences Inc (SLDB) has an institutional shareholding score of 7.00, placing it 80th out of 385 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 85.25%, which is a quarter-over-quarter decrease of 19.69%. Steven Cohen is the largest institutional …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

SLDB|Solid Biosciences Inc|Price:8.020|Chg%:+0.050

This article provides a comprehensive stock analysis of Solid Biosciences Inc (SLDB) from TradingKey. The company receives a strong overall stock score due to relatively healthy fundamentals, high growth potential, and high institutional ownership. Despite recent weak market performance, analysts generally rate SLDB as …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Solid Biosciences Inc (SLDB) has an earnings forecast score of 8.86, placing it 44th in the Biotechnology & Medical Research industry. Analysts provide an average price target of $15.00, with a high of $20.00 and a low of $9.00. Based on ratings from 14 …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Solid Biosciences Inc (SLDB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Solid Biosciences Inc (SLDB). It primarily highlights that the company has not yet disclosed relevant data for business segments, regional revenue, or profit contribution for various fiscal years and quarters. The only specific data point mentioned is …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Solid Biosciences Inc (SLDB) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Solid Biosciences Inc (SLDB), broken down into operating, investing, and financing activities. It presents financial data including net income, capital expenditures, and changes in working capital, alongside year-over-year percentage changes. The article …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Solid Biosciences Inc (SLDB) from TradingKey, noting its current valuation score of 6.20 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.12, comparing it to recent highs and lows, but states …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Solid Biosciences (SLDB) Proxy filing Summary

Solid Biosciences (SLDB) has released a proxy filing summary detailing the proposals for its annual meeting on June 10, 2026. Key items include the election of three Class II directors, the ratification of an independent auditor, and a proposal to increase authorized common stock …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Earnings Main company 🇺🇸 United States

SLDB stock trades around recent lows as Solid Biosciences updates gene therapy pipeline

Solid Biosciences Inc. (SLDB) stock is trading near recent lows, reflecting challenges in its early-stage gene therapy development. The company's financial reports for fiscal 2025 indicated narrowing losses and disciplined cost management, focusing on core programs and key clinical milestones. Investors are closely watching …

SLDB main company
Sharemaestro market context Trend signal active 52 weeks +55.1% SLDB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context